Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.47 - $7.63
Previous CloseN/A
Volume434.88K
Average Volume (3M)1.88M
Market Cap
$1.49B
Enterprise Value$1.89B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)78.4
Beta0.85
Next Earnings
Feb 26, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding275,777,680
10 Day Avg. Volume1,641,507
30 Day Avg. Volume1,876,892
Standard Deviation0.18
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.69
Price to Cash Flow (P/CF)40.70
P/FCF Ratio48.00
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.85
Enterprise Value/Ebitda26.66
Forecast
1Y Price Target
$9.75Price Target Upside72.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
MannKind News
PremiumCompany Announcements
MannKind Announces Upcoming Retirement of Lauren Sabella
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company is now durably cash flow positive and mostly de-levered, which is seen as positive for the fundamental outlook.
Pipeline PotentialAnalyst recommends an overweight rating on MannKind Corporation stock, highlighting potential growth in clinical programs MNKD-101 and MNKD-201.
Product ApprovalsTwo FDA approvals in diabetes and pulmonary arterial hypertension (PAH) have validated MannKind's technology platform in transforming therapeutics with proven efficacy into inhaled formulation to improve dosing convenience while maintaining or even improving treatment outcomes.
Bears Say
Commercial RisksCommercial risks associated with royalties could pose challenges to the company's profitability.
Risks And ChallengesRisks include clinical development challenges, commercial risks associated with royalties, and potential financial needs for raising capital.
Valuation ConcernsAfrezza makes up a small part of the valuation, and this is not expected to be needle-moving for the stock.
---
Ownership Overview
3.02% Insiders
12.14% Mutual Funds
14.36% Other Institutional Investors
56.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.47 and its highest was $7.63 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.49B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Nov 07, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is 0.03.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 275,777,680 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.04 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went down -0.677%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
---
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (72.26% Upside)
$9.75 (72.26% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.22%
12-Months-Change
Fundamentals
Return on Equity
-10.27%
Trailing 12-Months
Asset Growth
44.91%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
---
MNKD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment with strong revenue growth and successful collaborations driving optimism. However, challenges like Afrezza headwinds and market difficulties in NTM lung disease were noted.Read More>---
MNKD Stock 12 Month Forecast
Average Price Target
$9.75
▲(72.26% Upside)
Technical Analysis
Best Analysts Covering MNKD
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+36.60%
reiterated a buy rating 3 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +36.60% per trade.
---